Sam Miller

Cooley advised Founders Fund, a venture capital firm investing in smart people solving difficult problems, as a co-lead investor in Anduril Industries’ $1.5 billion Series F funding round, which increased Anduril’s valuation to $14 billion.

Cooley advised Vera Therapeutics, a clinical-stage biotechnology company, on its $115 million follow-on offering of common stock. Partners Jodie Bourdet and Kristin VanderPas led the Cooley team.

Cooley advised Vera Therapeutics on its $86 million follow-on offering of 55,742,026 shares of Class A common stock at a price to the public of $15.00 per share. Vera is a late-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunological diseases. Jodie Bourdet, Brett White and Alexa Ekman led the Cooley team.

Cooley advised Motive, a leading automated operations platform for the physical economy, on its $150 million Series F financing round, bringing the company’s valuation to $2.85 billion. Lawyers Rachel Burns and Rachel Proffitt led the Cooley team advising Motive.

Cooley advised Checkr, an HR technology company powering the future of work, on its $250 million Series E financing round, catapulting its valuation to $4.6 billion. Partner Calise Cheng led the Cooley team advising Checkr.